CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
The post Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss appeared first on MedCity News.
Leave a comment